Artikel

An aconomic perspective on recent advances in pharmacogenomics

---

SIGMA, JURNAL SAINS DAN TEKNOLOGI, Vol. 13, No. 1 Januari 2010, ABSTRAK : The sequencing of the human genome opened a new world of biomarkers. Is it possible to tell by a person's genetic signature how they would to a particular drug? This is the dream of "personalized medicine". At the moment many as half of all drug do not work for the people who take them. Such pharmacogenomics could also reduce the size and cost of clinical tests by allowing pharma firms to select the most suitable patients. But the reality is rather diferent.The difficulty lies in proving that they reliably correlate with cinical outcame.Companies that had placed theur faith in genomics are now cought in a dilemma: to produce information only or new drug. As the cost af gane sequencing has fallen, firm have rushed to offer genetic test directly to consumers, often raising grand expectation. There now seems to be a blacklash.Doctors have complained about being bypassed. Most generic test do not provide conclisive evidence of the risk of disease. Some academics also remain deeply skeptical about genomics being used in medicine. In addition, personalised medicine would be economic folly for firms who would need to develop a special pill for every patient. Traditionally firms sold conventional one-size-fits-all drug.Perhaps a better way would be mass cutomization

---

Ketersediaan

Informasi Detail

Judul Seri

-

No. Panggil

JURNAL

Penerbit

Yogyakarta : Universitas Sanata Dharma-LPPM., 2010

Deskripsi Fisik

Hal. 53-65.; 29 cm.; Hal. 64-65

Bahasa

Inggris

ISBN/ISSN

1410-5888

Klasifikasi

-

Tipe Isi

-

Tipe Media

-

Tipe Pembawa

-

Edisi

-

Subjek

BIOTECHNOLOGY
BIOMARKER
PHARMACOGENOMICS
GENOMICS
HUMAN GENOME
PERSONALIZED MEDICINE
DIAGNOSTICS
DNA
RNAS
SNP
TRANSGENES

Info Detail Spesifik

-

Pernyataan Tanggungjawab

SPILLAMEN, James J.

Versi lain/terkait

Lampiran Berkas

Komentar

---

Anda harus masuk sebelum memberikan komentar